July, 2025
July 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
28293031  
Rami Manochakian: Tarlatamab vs Chemotherapy in second treatment for advanced SCLC
Jun 3, 2025, 09:56

Rami Manochakian: Tarlatamab vs Chemotherapy in second treatment for advanced SCLC

Rami Manochakian, Vice President of the North American Neuroendocrine Tumor Society, shared on X:

“Hot Off The Press!
Just published in NEJM in conjunction with presentation at ASCO 2025.
Results of DeLLphi304 phase trial of Tarlatamab vs Chemotherapy in 2nd treatment for advanced Small Cell Lung Cancer.
  • mOS: 13.6 vs 8.3 months (HR: 0.6)
  • More Improvement in symptoms with Tarlatamab
  • ≥ Grade 3 AEs: 54% vs 80%
  • CRS and ICANS mostly grade 1/2.”

Rami Manochakian: Tarlatamab vs Chemotherapy in second treatment for advanced SCLC

Read OncoDaily’s special articles:

Tarlatamab (Imdelltra): Uses in Cancer, Side Effects, Dosages, Expectations, and More

Tarlatamab (Imdelltra): What Patients Need to Know About